Extractas Bioscience

Extractas Bioscience is an Australian pharmaceutical-ingredient company based in Tasmania and formerly known as Tasmanian Alkaloids. It is described as the largest opium-poppy processing company in Tasmania, a state with a significant regulated poppy-growing industry. The company processes alkaloid-bearing poppy material for pharmaceutical purposes under licences issued by both the Australian federal government and the Tasmanian state government. The business operates a processing plant at Westbury, west of Launceston in northern Tasmania. Its activities sit within a tightly controlled supply chain: poppies are cultivated by licensed growers, harvested material is processed to recover specific alkaloids, and the resulting ingredients are used in pharmaceutical manufacturing. The available reference material does not identify the full range of current customers, products, revenues, production volumes, or international destinations, so those details are not specified here. The company has operated under significant pharmaceutical-industry ownership. Tasmanian Alkaloids was a subsidiary of Abbott Laboratories as of 1980 and was later owned by Johnson & Johnson. The supplied material does not establish the date or terms under which the business adopted the Extractas Bioscience name, nor does it identify its current parent or owner. A notable technical development associated with the company was the patented Norman poppy variety. According to a 1999 Tasmanian Alkaloids Poppy Grower’s Bulletin, Norman was presented as the first poppy variety lacking morphine and codeine while retaining thebaine and oripavine. The variety entered commercial production in 1998. This development reflected the company's role not only as a processor but also as a participant in crop breeding and the development of poppy varieties tailored to particular alkaloid profiles. Extractas Bioscience's positioning is therefore centered on regulated botanical extraction, pharmaceutical alkaloid production, agricultural coordination, and specialist scientific capability. Its operations are distinct from consumer-facing healthcare brands: the company is primarily an industrial and business-to-business supplier operating within a government-supervised pharmaceutical raw-material system. Publicly available information in the supplied references is limited, and further research would be required to document its present ownership, management, product portfolio, certifications, markets, and corporate structure.

Extractas Bioscience traces its public identity to the company formerly known as Tasmanian Alkaloids. The business developed within Tasmania's regulated opium-poppy industry, where licensed cultivation and processing support the production of pharmaceutical alkaloids. Its processing plant is located at Westbury, west of Launceston in northern Tasmania. The company has been associated with major pharmaceutical corporations during its history. The supplied reference identifies Tasmanian Alkaloids as a subsidiary of Abbott Laboratories as of 1980. It was subsequently a subsidiary of Johnson & Johnson, although the available material does not provide the relevant transaction dates, ownership percentages, or the duration of Johnson & Johnson's ownership. The date on which the Tasmanian Alkaloids name changed to Extractas Bioscience is also not established by the supplied sources. A significant part of the company's scientific history concerns poppy breeding and the selection of alkaloid profiles. The company patented the Norman poppy variety, which was described in its 1999 Poppy Grower’s Bulletin as the first variety without morphine and codeine while retaining thebaine and oripavine. Norman entered commercial production in 1998. The development illustrates the commercial importance of producing poppy varieties whose chemical composition is suited to pharmaceutical processing and regulatory requirements. The company's work has required formal government authorization. Extractas Bioscience, under its former Tasmanian Alkaloids identity, has been licensed by both Australian federal and Tasmanian state authorities to conduct opiate-processing activities. Such licensing reflects the controlled nature of the relevant crops, substances, facilities, and supply chains. The available reference material does not provide a complete chronology of the company's establishment, ownership changes, plant expansion, product launches, leadership, financial performance, or present corporate structure. It does, however, establish a continuous identity linking Extractas Bioscience with Tasmanian Alkaloids and identifies the business as a major Tasmanian processor of opium-poppy material for pharmaceutical use.

• 1999

  Norman variety described in the growers' bulletin

  [1]Extractas Bioscienceen.wikipedia.org

  A Tasmanian Alkaloids Poppy Grower’s Bulletin described Norman as the first variety of its stated type, documenting the company's crop-development work.

• 1998

  Norman poppy enters commercial production

  [1]Extractas Bioscienceen.wikipedia.org

  The Norman poppy variety associated with the company entered commercial production. It was developed to provide a distinctive alkaloid profile, lacking morphine and codeine while retaining thebaine and oripavine.

• 1980

  Tasmanian Alkaloids identified as an Abbott Laboratories subsidiary

  [1]Extractas Bioscienceen.wikipedia.org

  The reference material identifies Tasmanian Alkaloids as a subsidiary of Abbott Laboratories as of 1980.

• Business adopts the Extractas Bioscience name

  [1]Extractas Bioscienceen.wikipedia.org

  The company formerly known as Tasmanian Alkaloids became known as Extractas Bioscience. The supplied reference does not specify the date or circumstances of the rebranding.

A regulated Australian producer and processor of poppy-derived pharmaceutical alkaloids, combining agricultural supply-chain management, crop development, and specialist extraction.

• Agricultural variety · 1998

  Norman poppy

  Norman is a patented opium-poppy variety associated with Extractas Bioscience's former Tasmanian Alkaloids identity. It was described in a 1999 company growers' bulletin as lacking morphine and codeine while retaining thebaine and oripavine. The variety entered commercial production in 1998 and demonstrates the company's involvement in developing crops for specialized pharmaceutical alkaloid processing.

• Pharmaceutical ingredients

  Poppy-derived pharmaceutical alkaloids

  The company's core activity is the processing of legally cultivated opium poppies into pharmaceutical alkaloid materials. The supplied sources identify the business as a major Tasmanian opium-poppy processor but do not provide a complete current product catalogue, specifications, or named commercial formulations.

1. 1Extractas Bioscienceen.wikipedia.org